Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive July 1, 2011	Precious Mettle Taking Onyx Pharmaceuticals to new heights: CEO Tony Coles talks about the midsize company's transition from adolescence to adulthood.
Pharmaceutical Executive December 1, 2011 Ben Comer	Pharm Exec's 2012 Pipeline Report It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle?
Pharmaceutical Executive December 1, 2010 Walter Armstrong	The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA
BusinessWeek June 13, 2005 Catherine Arnst	Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins.
The Motley Fool February 13, 2007 Brian Lawler	Rock-Solid News From Onyx Results show that the drug Nexavar works in another type of cancer. But investors need to consider other issues when taking a closer look at this pharma.
Chemistry World July 2010 Anna Lewcock	Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition.
Pharmaceutical Executive November 1, 2013 Ben Comer	2014 Pipeline Report: The Sprint to Value Across a constellation of categories, bright new drugs are moving into position. The pharma model may have changed, but companies are keeping their blockbusters.
Pharmaceutical Executive December 1, 2008 Ron Feemster	The 2008 Pipeline Report We scrub industry's pipeline to find the drugs that everyone will be talking about in 2009 and beyond.
Pharmaceutical Executive December 1, 2005 Ron Feemster	The PharmExec 2005 Pipeline Report Dry? Not quite. Instead of 1990s-style blockbusters, pharma's new molecules are niche drugs, cancer treatments and -- at last -- innovative mechanisms for troublesome targets: Acomplia [rimonabant] by Sanofi-Aventis... AMG 162 [denosumab] by Amgen... etc.
Pharmaceutical Executive November 1, 2012	Pharm Exec's 2013 Pipeline Report In this year's report, Ben Comer reveals that drug approvals are up, as new discoveries in biology peel away symptomology to expose underlying causes.
The Motley Fool June 13, 2007 Brian Orelli	Evaluating a One-Trick Pony There is no doubt that investors should have bought Onyx Pharmaceuticals at its lows last December: The stock has tripled since then. The more important question is, what should you do now? Let's take a look at where Onyx is going.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
BusinessWeek August 26, 2010 Tom Randall	Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer.
The Motley Fool August 9, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool June 6, 2011 Luke Timmerman	Exelixis Zeroes In on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients Is Exelixis' risky bet about to pay off?
The Motley Fool October 27, 2010 Ralph Casale	Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment.
The Motley Fool August 8, 2007 Brian Orelli	Onyx Is Almost There Onyx Pharmaceutical narrowed losses for the quarter, and things should improve even more in the months to come, even as their bottom line is still being hampered by endless clinical trials.
The Motley Fool April 28, 2009 Brian Orelli	Headline? Bad! Unexpected? No! For a company that only has one drug on the market, stopping a failing phase 3 clinical trial that's designed to expand the market of that drug is usually a major blow. But Onyx Pharmaceuticals was able to shrug it off.
Pharmaceutical Executive November 1, 2014 Josh Baxt	2015 Pipeline Report: Burning Bright The science of drug discovery is back on script and the stars are cued up for a new generation of breakthrough therapies.
The Motley Fool May 31, 2011 David Williamson	Roundtable: The World's Best Biotechs Motley Fool analysts choose these as their favorite biotech stocks: Aeterna Zentaris... Seattle Genetics... BioMarin Pharmaceutical... Amarin...
The Motley Fool June 15, 2010 Brian Orelli	Just Enough to Give Investors Hope Hitting a secondary endpoint means all is not lost for Onyx's lung cancer drug.
The Motley Fool April 21, 2011 Brian Orelli	Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested.
The Motley Fool October 12, 2009 Brian Orelli	Onyx Strikes Gold A nice pipeline pickup for this pharmaceutical company.
Pharmaceutical Executive July 1, 2011 Dickmeyer & Rosenbeck	From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition?
The Motley Fool March 22, 2005 Charly Travers	Do Good Drugs Guarantee Investment Success? By the time you know a drug is good, are you late to the party? Instead of trying to catch a train that has already zipped by, try investing in drug programs well in advance of phase 3 trials.
The Motley Fool February 26, 2011 Brian Orelli	FDA Applications and a Look Ahead It isn't pretty.
The Motley Fool July 12, 2010 Ryan McBride	Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009.
The Motley Fool February 21, 2008 Brian Orelli	Onyx's Double Dose of Trouble Poor clinical trial data and a lack of profits hit the drugmaker hard. Investors, take note.
The Motley Fool May 28, 2009 Brian Orelli	Make Money, Fight Disease: The ASCO Preview The big cancer meeting is upon us.
The Motley Fool June 5, 2007 Billy Fisher	Onyx on Fire It is readily apparent that investors in the biopharma will sink or swim on the future results of Nexavar. The ASCO meeting marks an integral win for the company, but only time will tell whether the drug can push the company into the black.
The Motley Fool October 8, 2010 Luke Timmerman	Onyx Delays Cancer Drug Application As FDA Asks for More Data Shares fell about 7% in after-hours trading Thursday evening.
The Motley Fool June 21, 2007 Brian Lawler	Onyx on the Clock The one-drug wonder's partner files a marketing application to expand the use of its lead drug. Investors, take note.
The Motley Fool May 4, 2009 Robert Steyer	Beyond Provenge -- The Next Hot Cancer Drug? The search for prostate cancer treatments is filled with prospects and littered with failures. Which companies have the best chance of success?
The Motley Fool August 27, 2007 Brian Orelli	Onyx: Old News Is Good News Onyx set a 52-week high today, even though the good news wasn't all that new. After the recent dearth of FDA approvals, investors may be flocking to a drug that's nearly certain to get the agency's thumbs-up.
The Motley Fool June 9, 2010 Brian Orelli	ASCO Pops and Drops Themes and company news from the annual meeting of the American Society of Clinical Oncology.
The Motley Fool December 29, 2011 Brian Orelli	What to Look for From Keryx and Aeterna Zentaris in 2012 The future is uncertain for these pharmaceutical companies.
The Motley Fool August 18, 2010 Travers & Greer	Dendreon's Big Pharma Future Dendreon has had success with its prostate cancer treatment Provenge. What does Provenge's success mean for the future of Dendreon?
The Motley Fool June 28, 2007 Brian Orelli	Onyx's Hard at Work Onyx's future depends on getting Nexevar approved for new indications. The liver cancer expansion is a nice start, and it should bring Onyx into the black. Investors, take note.
The Motley Fool June 4, 2010 Brian Orelli	This Cancer Drug's on a Roll Novartis' Afinitor scores another win.
Pharmaceutical Executive May 1, 2007 Patrick Clinton	The Topic of Cancer What will tomorrow's cancer commercialization model really look like? We asked four heavyweights from the world of oncology what they thought.
The Motley Fool March 30, 2010 Brian Orelli	Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers.
The Motley Fool May 14, 2007 Brian Lawler	Onyx Rocks The oncology-focused biotech announces first-quarter financial results. Investors, take note.
The Motley Fool May 7, 2008 Brian Orelli	Black Onyx, but Not for Long Onyx posts a stellar quarter, but earnings for the pharmaceuticals company are headed in the other direction for the rest of the year.
Pharmaceutical Executive November 1, 2006 Patrick Clinton	Man in a Hurry Bureaucratic? Bayer? Not if you ask Arthur Higgins. In just over two years, the head of Bayer HealthCare has proved that pharma can be a quick and nimble business.
Pharmaceutical Executive February 1, 2013 William Looney	Pathways to Progress Cancer is increasingly understood as a collection of rare and mostly treatable conditions rather than the impregnable, monolith portrayed in popular culture. Industry experts review current and pending efforts to turn great science into good practice.
The Motley Fool April 13, 2011 Brian Orelli	Drug Duo Escapes Advisory Panel Unharmed Pfizer and Novartis are on their way to expanding their cancer drug indications.
The Motley Fool October 26, 2010 Ralph Casale	Where We Are in the War on Cancer A summary of the roundtable discussions at Xconomy's recent event, "Boston's War on Cancer."
The Motley Fool April 14, 2011 Brian Orelli	Human Genome Sciences Will Be Profitable, Eventually With its first drug on the market -- nearly 20 years after the company was founded -- Human Genome Sciences should start to show meaningful revenue this year.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
Pharmaceutical Executive April 1, 2006 Joanna Breitstein	HBA Woman of the Year: Susan Desmond-Hellman There are people who hope cancer, one day, will become a manageable disease. Then there are those who know it. Meet Susan Desmond-Hellmann.